|
|
Transmedics Group Inc (TMDX) |
|
Price: $56.7700
$-0.14 
-0.246%
|
| Day's High:
| $58.5908
| Week Perf:
| 2.53 %
|
| Day's Low: |
$ 56.71 |
30 Day Perf: |
-11.67 % |
| Volume (M): |
671 |
52 Wk High: |
$ 99.63 |
| Volume (M$): |
$ 38,104 |
52 Wk Avg: |
$67.72 |
| Open: |
$57.22 |
52 Wk Low: |
$38.86 |
|
|
| Market Capitalization (Millions $) |
1,848 |
| Shares
Outstanding (Millions) |
33 |
| Employees |
194 |
| Revenues (TTM) (Millions $) |
151 |
| Net Income (TTM) (Millions $) |
-18 |
| Cash Flow (TTM) (Millions $) |
552 |
| Capital Exp. (TTM) (Millions $) |
8 |
Transmedics Group Inc
TransMedics Group Inc. (NASDAQ: TMDX) is a medical technology company headquartered in Andover, Massachusetts that is dedicated to improving organ transplant outcomes. The company was founded in 1998 and has since developed innovative solutions to maintain organ viability during transportation, known as the Organ Care System (OCS).
The OCS is a portable platform that enables organ transplants by providing uninterrupted blood flow, oxygenation, and preservation of organs during transportation. The OCS is compatible with a variety of organ types, including hearts, lungs, and livers, and has been shown to increase the number of organs suitable for transplantation and improve transplant outcomes.
TransMedics is focused on increasing patient access to transplants by improving organ preservation and reducing the risk of transplant-related complications. The company is dedicated to delivering innovative tools and services that can significantly increase the number of organs available for transplantation.
The company has a global presence, with a presence in Europe, the United States, and Asia. TransMedics has commercialized the OCS in over 30 countries and has obtained regulatory approval for its products from major regulatory authorities, including the United States, Europe, Canada, and Australia.
TransMedics has also received numerous awards and accolades for its innovative technology, including being named a finalist in the 2021 Edison Best New Product Awards for its OCS LUNG platform.
TransMedics is positioned for continued growth, with a strong pipeline of ongoing clinical trials and a dedicated team of experts working to develop new solutions that are transforming the field of organ transplant medicine. The company is committed to bringing its innovative technologies to organ transplant patients around the world, providing hope and new opportunities for those in need of life-saving transplants.
Company Address: 200 Minuteman Road Andover 1810 MA
Company Phone Number: 552-0900 Stock Exchange / Ticker: NASDAQ TMDX
| TMDX is expected to report next financial results on November 03, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Fonar Corporation
In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment and Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery.
Financial Performance
Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment and Supplies sector as a whole.
|
|
Precision Optics Corporation Inc
Precision Optics Corporation Inc (POCI) has experienced a slight increase in its stock value over the past week, rising by 0.66%. Additionally, its stock currently trades 6.5% above its 52-week low. These figures indicate positive performance for the company in the stock market.
Examining POCI's financial report for the fourth quarter of 2023, it is evident that the company faced a net loss per share of $-0.11. This represents a decline from the $0.08 per share profit reported in the previous year. However, despite the loss, POCI saw a 4.811% increase in revenue, reaching $5.02 million compared to the corresponding reporting period the previous year.
|
|
Heart Test Laboratories Inc
Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
|
|
Sensasure Technologies Inc
Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.
|
|
Innovage Holding Corp
Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.55 $ |
| Revenues (TTM) |
4.64 $
|
| Cash Flow (TTM) |
16.96 $ |
| Cash |
17.89 $
|
| Book Value |
4.46 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.55 $
|
| Revenues (TTM) |
4.64 $ |
| Cash Flow (TTM) |
16.96 $ |
| Cash |
17.89 $
|
| Book Value |
4.46 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
